Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEN-10755 in Progressive Hormone Refractory Prostate Cancer
NCT00027781Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2001
- Primary completion
- Mar 2003
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of Sabarubicin in prostate cancer (PCa), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Objective PSA Response Rate. Started Aug 2001; status: completed.
02
Drugs
Sabarubicin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00027781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027781.